Skip to main content
  • Research article
  • Open access
  • Published:

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection



Treatment of chronic hepatitis C virus infection with direct acting antiviral therapy results in viral elimination in over 90% of cases. The duration of treatment required to achieve cure differs between individuals and relapse can occur. We asked whether cellular and transcriptional profiling of peripheral blood collected during treatment could identify biomarkers predictive of treatment outcome.


We analyzed peripheral blood collected during treatment of genotype 1 HCV with 24 weeks of sofosbuvir and weight-based or low dose ribavirin in a trial in which 29% of patients relapsed. Changes in host immunity during treatment were assessed by flow cytometry and whole blood gene expression profiling. Differences in expression of immune-relevant transcripts based on treatment outcome were analyzed using the Nanostring Human Immunology V2 panel.


Multiple cellular populations changed during treatment, but pre-treatment neutrophil counts were lower and natural post-treatment killer cell counts were higher in patients who relapsed. Pre-treatment expression of genes associated with interferon-signaling, T-cell dysfunction, and T-cell co-stimulation differed by treatment outcome. We identified a pre- and post-treatment gene expression signature with high predictive capacity for distinguishing treatment outcome, but neither signature was sufficiently robust to suggest viability for clinical use.


Patients who relapse after hepatitis C virus therapy differ immunologically from non-relapsers based on expression of transcripts related to interferon signaling and T-cell dysfunction, as well as by peripheral neutrophil and NK-cell concentrations. These data provide insight into the host immunologic basis of relapse after DAA therapy for HCV and suggests mechanisms which may be relevant for understanding outcomes with currently approved regimens.

Peer Review reports


Over 90% of patients with chronic hepatitis C virus (HCV) infection achieve a sustained virologic response (SVR) after 8–12 weeks of treatment with currently approved direct acting antivirals (DAAs). When 4–6 week courses of treatment are given, treatment failures are unacceptably high. Such failures could relate to drug potency, drug susceptibility of the virus, virus replication levels, and patient adherence, but host factors may also play a role [1,2,3,4,5,6].

Although race, gender, liver disease stage, baseline viral load, viral genotype, and concomitant medications have correlated with population odds of achieving SVR in some studies, there are currently no clinically reliable predictors of treatment response [6]. Pre-treatment HCV resistance-associated variants (RAVs) associate with relapse with some regimens [7, 8], but existence of RAVs alone cannot predict outcomes in individuals and other factors must be involved [4, 9]. We and others observed higher expression of functional markers of innate, interferon-related, and adaptive immune function in patients who achieved SVR with DAA therapy relative to patients who relapsed [10,11,12,13,14,15,16]. We thus hypothesize there is a role for host immunity in modulating, or at least reflecting, the odds of achieving SVR.

Specifically, our analysis of liver biopsies from HCV-infected patients treated with sofosbuvir and ribavirin identified higher post-treatment expression of interferon-related genes in patients achieving SVR, suggesting induction of endogenous type-I interferon activity during therapy may facilitate SVR [14]. In a separate study of PBMCs from two sofosbuvir-based DAA trials, we observed dynamic changes in the composition of peripheral blood during treatment [16], suggesting altered migration of peripheral immune cells during treatment may have relevance for understanding the role of intrahepatic and systemic immunity in viral clearance.

In this study, we combine these observations and ask whether immune markers in peripheral blood before and after treatment with sofosbuvir and ribavirin differed between patients achieving SVR vs. those who relapsed. Patient adherence to antiviral treatment in this trial did not differ based on treatment outcome, but relapse was common, occurring in 29% of subjects [17]. The regimen of sofosbuvir and ribavirin for the treatment of genotype 1 HCV infection is no longer in clinical use due to unacceptably high rates of relapse relative to currently approved therapies. Because relapse was common in this trial, close analysis of longitudinal samples collected during the trial presented an opportunity to understand the mechanistic underpinnings of virologic relapse, which are likely relevant for understanding why relapse can occur with currently approved regimens, albeit less frequently.


Clinical cohort

Clinical samples collected as part of the SPARE clinical trial (NCT01441180) were used in this study. SPARE was a trial conducted at the National Institute of Allergy and Infectious Diseases (NIAID) in which patients infected with HCV genotype-1 were treated with sofosbuvir and weight-based or low dose ribavirin for 24 weeks, as previously described [14, 17]. This study received approval from the Institutional Review Boards at NIAID and the Medical University of South Carolina and was conducted in concordance with the 1975 Declaration of Helsinki. All patients provided written informed consent, as previously reported with initial publication of the clinical trial result [17], which included permissions to use samples and data collected in the trial for future studies.

Flow cytometry

Immuno-phenotyping of peripheral blood drawn into EDTA-containing blood collection tubes was performed using a modification of the Centers for Disease Control and Prevention guidelines in a Clinical Laboratory Improvement Act-certified laboratory, as previously described [16]. Cells were stained with combinations of monoclonal antibodies and then lysed with Optilyse-C (Beckman Coulter, Hialeah, FL), washed twice, and re-suspended in 500 μl of phosphate-buffered saline (Cambrex, Walkersville, MD). Samples were analyzed immediately on a Becton Dickinson FacsCanto flow cytometer (BDBiosciences, San Jose, CA). 4-color antibody panels used for cellular identification and enumeration have been previously described [16].

Lymphocytes were identified by side scatter and CD45 staining, with confirmation that less than 5% of cells within the lymphocyte gate expressed CD14 [18]. Absolute concentrations of specific lymphocyte populations (CD3+, CD4+, CD8+, CD4+/8+, CD19, and CD16+/56+ lymphocytes) were calculated using the measured percentage of each cell type within the lymphocyte gate and the absolute lymphocyte concentration [16].

Gene expression analysis

Whole blood was collected into PaxGene RNA tubes at the time of venipuncture either pre-treatment or at the end of treatment, prior to virologic relapse, and was stored at − 80 °C until processing. Paired blood samples were available from 40 subjects enrolled in the trial, including 24 who achieved SVR and 16 who relapsed. RNA was extracted using the PAXgene Blood miRNA Kit (Qiagen) according to the manufacturer’s instructions. RNA quality was assessed using the Agilent Bioanalyzer. RNA samples had a median RNA integrity number (RIN) of 7.2 and most (91%) had an RIN greater than 6.5.

A Nanostring nCounter was used to directly quantitate expression of 579 immune transcripts (Human Immunology v2 Panel). The lower limit of detection is 20 counts, and as such, counts below 25 were considered to be background signal and counts below 100 were considered to be semi-quantitative. Genes in which 30% or more of samples had a count under 100 were excluded from subsequent analysis. Normalization of gene expression was performed relative to housekeeping genes using the GeNorm algorithm. Of 15 housekeeping genes included on the panel, 11 with the lowest standard deviation after normalization were used (all with SD < 0.30). Data were Z-score transformed and grouped by unsupervised clustering. Mean Square Error analysis identified 4 samples with low data quality, and as such these and their paired samples were excluded from further data analysis, yielding a final dataset of 36 paired samples (n = 23 SVR, n = 13 relapse). Demographic characteristics of these 36 patients are shown in Table 1. More subjects had advanced liver fibrosis (HAI fibrosis 3–4) in the relapse group (n = 8) than the SVR group (n = 5). Validation of expression for select genes was performed using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), as previously described [14].

Table 1 Demographic Profile of Patients Included in Whole Blood Transcriptional Analysis

Immune cell profiling

Advanced Analysis Immune Cell Type Profiling was performed with nSolver software to predict changes in cell type frequencies based on measured expression of gene sets validated to be cell-type specific (Supplemental Table 1) and was compared to data independently derived by flow cytometry [19].

Statistical analysis

All statistical analyses on NanoString data were performed on log2 transformed normalized counts. Differential expression analyses were carried out using nSolver4.0 and Advanced Analysis package 2.0 (NanoString tm), following the default analysis pipeline. A machine learning algorithm based on Elastic Net, a regression method that applies both the lasso and ridge penalties, was used to discover gene expression signatures that differentiate relapse and SVR patients both pre- and post-treatment. Curated, log2 transformed expression data was used to generate a linear predictor score = ∑Xiβi (X = gene X expression level; β = coefficient). Cross-validation runs were performed to select the strength of each penalty and for estimation of AUC based on the training data set. Demographic and flow cytometry data were analyzed by Chi-square or t-test methods as indicated.


To test the hypothesis that immune differences during DAA treatment associate with treatment outcome, we analyzed peripheral blood from the SPARE trial in which a significant number of patients experienced treatment relapse (29%) [17]. We first examined changes in the cellular composition of peripheral blood over the course of treatment by flow cytometry. We observed a significant decrease in the concentration of total lymphocytes, NK-cells, B-cells, CD4+ T-cells, and CD8+ T-cell during treatment when considering the entire patient cohort (Fig. 1a). We had not observed these declines in data from previously published ribavirin-free DAA cohorts [16], and suspect they may reflect an impact of ribavirin on overall leukocyte counts, as previously reported [20]. We also observed a significant relative increase in neutrophil and CD14+ monocytes cell concentrations over the course of treatment (Fig. 1a).

Fig. 1
figure 1

Cellular changes during DAA therapy as measured in peripheral blood by flow cytometry and as predicted by gene expression analysis. a Changes in cellular populations determined by flow cytometry, as described in the methods section. Data are derived from up to 53 patients for each individual cell type. b Change in predicted cellular composition of total PBMCs using Nanonstring score. Data are derived from 36 patients. Significance was determined by paired t-test with designation on graphs of p < 0.05 (*), p < 0.005 (**), p < 0.0005 (***)

We next analyzed predicted changes in cellular concentrations calculated by transcriptional analysis of whole blood using the Nanostring Immune Cell Type Profiling platform. Nearly identical results were obtained, as B-cells, NK CD56-dim cells, total T-cells, Th1 cells, cytotoxic CD8+ T-cells, and exhausted CD8+ cells were all predicted to decrease over the course of treatment, while CD45+ cells (a leukocyte marker) and neutrophils were predicted to increase (Fig. 1b). The similarity of findings derived by different techniques suggests whole blood transcriptional profiling was a valid approach to provide meaningful and biologically relevant insight.

We next examined whether cellular populations differed pre- or post-treatment based on outcome. Pre-treatment, only neutrophil concentration differed by outcome, with relapsers having lower neutrophil concentration as assessed by both flow cytometry and gene expression profiling (Fig. 2a). Post-treatment, relapsers had higher concentrations of NK-cells by flow cytometry (Fig. 2b), but no other significant differences (data not shown). By gene expression profiling, relapsers had higher predicted concentrations of NK cells and cytotoxic cells, and a trend towards higher concentrations of total CD8+ T-cells and exhausted CD8+ T-cells (Fig. 2b).

Fig. 2
figure 2

Significant differences in cell type frequency between patients achieving SVR versus patients who relapsed. a Pre-treatment, only neutrophil count differed based on eventual treatment outcome, and was found to be lower in relapsers. b Post- treatment changes of significance as determined by flow cytometry or Nanostring score. Statistical analysis was by unpaired t-test, with p-values displayed

We next analyzed expression of individual transcripts and examined changes with treatment and differences by outcome. In the entire patient cohort, 208 genes changed significantly during treatment (Fig. 3a, Supplemental Excel File Tab 1), a substantial percentage of the total genes tested. Multiple ISGs decreased with treatment (e.g. MX1, IFIT2, CXCL10, RARRES3), consistent with prior results from other DAA trials [14, 21, 22]. IFNAR1 and IFNAR2, which comprise the type-I interferon receptor, both had increased expression post-treatment. Genes associated with T-cell activation (e.g. CD80, CD160, LAG3, BTLA, ICOS) decreased with treatment. An analysis of the data by hierarchical clustering to examine any impact of gender, IFNL4 genotype, fibrosis stage, ribavirin dose, and pre-treatment ALT levels, several of which differed based on outcome in this patient cohort (Table 1), did not identify clear clustering based on these factors (Supplemental Fig. 1).

Fig. 3
figure 3

Volcano plot for genes that change over time in the entire patient cohort (a), or that have differential expression pre- (b) or post-treatment (c) based on treatment response. For A, genes in green with a negative log fold change had decreased expression during treatment, while genes in red with a positive fold change had increased expression. For B-C, genes with a negative fold change (in green) had lower expression in relapsers compared to patients achieving SVR, while genes with a positive fold change (in red) had higher expression in relapsers. Genes with labels have a p-value < 0.05 and a fold change of 1.5 or greater

We next analyzed differences by treatment outcome and identified 84 genes pre-treatment and 43 genes post-treatment with differential expression (Fig. 3b-c, Supplemental Excel File Tabs 2–3). Significant genes with the highest fold differential expression between SVR and relapse patients pre- and post-treatment are displayed as heatmaps (Fig. 4).

Fig. 4
figure 4

Genes with the highest differential expression between SVR and relapse in whole blood either pre- (a-b) or post- treatment (c). Delta log2 gene expression was determined for each patient in relation the mean expression for the cohort and all displayed genes achieved significance. P-values for (b) were determined by unpaired t-test

Pre-treatment, prior to DAA exposure, a number of genes related to TLR-mediated pathogen recognition (TLR8, TLR2, TLR5, IRAK4, TOLLIP), IL1 signaling, complement activation, and TNF signaling had lower expression in patients who later experienced treatment relapse. Multiple genes related to neutrophils (FCGR3A/B, FCGR2A, FCGR2A/C) were lower in relapsers, consistent with observations derived by flow cytometry. Interestingly, pre-treatment expression of IFNAR1, IFNAR2, and SOCS3 was lower in relapsers, while pre-treatment expression of SOCS1 was higher (Fig. 4a and Supplemental Excel File Tab. 2). SOCS3 and SOCS1 are known negative regulators of interferon signaling. Several genes associated with T-cell dysfunction/tolerance (CTLA4-TM, CD244, IDO1) had higher pre-treatment in patients who subsequently relapsed.

Post-treatment, several consistent changes distinguished the groups by outcome. First, patients who relapsed had higher expression of genes related to NK-cell frequency and function (KLRK1, KLRD1, KLRG1, NCR1, KLRC3, KLRC4, PRF1, GZMB), which includes both activating and inhibitory receptors, consistent with data derived by flow cytometry. In addition, patients who relapsed had higher expression of genes associated with T-cell dysfunction (HAVCR2, KLRG1, CD244).

Finally, we asked whether expression of any gene or combination of genes pre-or post-treatment could have sufficient capacity to robustly predict clinical outcome. Using a machine learning algorithm, we identified a 12-gene pre-treatment and an 5-gene post-treatment set with high predictive capacity in training sets with AUCs of 0.95 and 0.86, respectively (Supplemental Figs. 23). As we lacked data from an independent cohort to validate these gene signatures, we performed an internal validation analysis and found neither signature had a consistently high AUC on cross-validation runs, both with mean AUCs of 0.66 (Supplemental Figs. 23).


This study asked whether analysis of routinely available clinical samples could distinguish HCV patients who relapse or achieve SVR after treatment with sofosbuvir and ribavirin and provide insight into mechanisms of relapse. While the antiviral regimen of sofosbuvir and ribavirin is no longer in routine clinical use, the high rates of relapse that occurred in the study offered an opportunity to identify biologic correlates of relapse that likely remain relevant when trying to understand mechanisms of relapse that occur with currently approved DAA regimens. We identified differences in neutrophil count pre-treatment and NK cell count post-treatment that distinguish patients by outcome. In addition, whole blood expression of transcripts related to interferon signaling, T-cell dysfunction, and NK-cells distinguished patients by treatment outcome. These data provide evidence that heightened IFN signaling and dysregulated adaptive immunity pre-treatment associate with higher odds of relapse.

Pre-treatment, our primary observation was that neutrophil count was lower in eventual relapsers and that expression of genes related to pathogen detection, neutrophil function, and interferon signaling differed by outcome. While multiple canonical ISGs decreased during treatment and did not differ by treatment outcome (e.g. CXCL10, RARRES3, MX1), we were intrigued to find that expression of both IFNAR1 and IFNAR2 increased with treatment, suggesting an inverse correlation between type-I receptor expression level and interferon signaling. These data are consistent with previous reports that IFNAR1 gene expression is reduced in PBMC of chronic HCV patients [23]. Our observation that patients who relapsed had lower baseline expression of both IFNAR1 and IFNAR2 thus suggests a heightened state of interferon signaling pre-treatment. This observation suggests that, as was trued for interferon-based therapy [24], heightened interferon signaling pre-treatment may reflect a poor antiviral immune state less amenable to HCV clearance, and thus more prone to relapse.

Although type-I and type-III IFN signaling induce a similar ISG transcriptional profile in cells expressing both receptors, the pattern of genes is not identical and the kinetics of induction can differ [25]. As noted above, the expression of SOCS1, a negative regulator of IFN signaling, decreased during treatment, consistent with the pattern observed for other ISGs. Expression was higher pre-treatment in relapsers, which was the inverse pattern of that observed with IFNAR1 and IFNAR2. This data is intriguing as type-III IFN signaling has previously been shown to selectively induce SOCS1 relative to type-I IFN signaling in human and chimpanzee liver [26, 27], suggesting the chronic IFN signature in HCV patients could relate to type-III IFN signaling. Whether the lower neutrophil count we observed pre-treatment in relapsers reflects higher levels of endogenous interferon signaling, as interferon treatment causes a relative neutropenia [28, 29], requires further study. This observation regarding neutrophils, which contribute significantly to the cellular composition of whole blood analyzed by gene expression profiling, is of particular interest as neutrophils are excluded from most analyses examining PBMCs. Taken together, these data suggest higher baseline IFN activation in patients who subsequently relapsed.

Post-treatment, relapsers had higher levels of NK cells and NK-cell associated transcripts than patients achieving SVR. This is intriguing as changes in NK cell function and frequency during DAA therapy have been previously reported, with most observing decreases during HCV treatment, including reduced surface expression of NKp30 (NCR3), NKp46 (NCR1), TRAIL, and NKG2A [10, 30]. Our data suggests NK-cell frequency and relative activation state post-treatment could reflect presence of residual intrahepatic HCV. While NKp30 and NKG2A were not analyzed in this study, we found no change in TRAIL or NKp46 expression during treatment, but did find higher expression of the activating receptor NKp46 post-treatment in relapsers. Our data are also intriguing in the light that IFNL genotype and IFN activity have been linked to differential NK cell activation [31,32,33,34]. As understanding NK-cell functional status from whole blood gene expression profiling is challenging, our data support future experiments focused on analysis of NK-cell phenotype at the end of treatment.

Another major finding of the study relates to genes associated with T-cell dysfunction. We observed significantly higher post-treatment expression of markers of T-cell exhaustion in relapsers including HAVCR2 (TIM3) and KLRG1 (Fig. 4) [35] .While CTLA-4-TM decreased over the course of treatment in the entire cohort, relapsers had higher pre-treatment expression. In addition, while 2B4 (CD244) did not change during treatment, patients who relapsed had higher expression both pre- and post-treatment. Taken together, these data associate relapse with T-cell dysfunction, consistent with prior findings derived by flow cytometry [10,11,12,13,14,15]. Prior work identified a heterogenous response to in vitro blockade of inhibitory co-stimulatory receptors (PD1, CTLA4, TIM3, 2B4) for the CD8 response in patients with HCV infection [36], and may reflect distinct ways in which individual hosts respond to the same pathogen, which could have relevance for treatment relapse. In our study we observed no change in PDL1 (CD274) during treatment and no difference pre- or post-treatment based on treatment outcome, while expression of PD1 (PDCD1) was low and did not satisfy the stringency criteria of this analysis. As IFN-driven signaling can cause T-cell exhaustion, which can be reversed with IFN blockade [37], our data suggesting heightened interferon signaling pre-treatment in relapsers may thus relate mechanistically to parallel observations of higher T-cell dysfunction in relapsers.

Together, these data suggest relapsers might be more likely to respond if they could be identified prospectively, and if the rate of their immune restoration on DAA therapy could be identified and considered when considering treatment duration. Given the high efficacy of currently approved DAA regimens, it is intriguing to consider that subjects experiencing more rapid immune “rejuvenation” could achieve cure with shortened treatment durations, while those with a more sluggish immune response on therapy may benefit from a longer course of treatment to minimize the risk of relapse. When considering other regulators of T-cell activation [38], we did observe down-regulation of CD80, CD160, LAG3, BTLA, and ICOS with treatment (Fig. 4, Supplemental Excel File Tab 1), but saw no difference at any time point based on treatment outcome.

A limitation of our study is that most transcripts are not cell-type specific. As such our suggestions regarding mechanism and causation require prospective validation. Other limitations include the low number of patients with IFNL4 genotype predicting inability to produce IFNL4 protein, limiting our capacity to analyze difference in gene expression patterns attributable to this. Although more patients with advanced fibrosis were present in the group of patients who relapsed (Table 1), which could have confounded our analysis, we did not identify an association of fibrosis with the gene expression patterns that correlated with relapse in this study. While we did not identify an impact of ribavirin dose on the reported results, because ribavirin can impact gene expression and impart sensitization to IFN signaling [39] an impact of ribavirin dose on these findings cannot be ruled out [17]. Finally, as discussed above, sofosbuvir and ribavirin is not currently in clinical use for treatment of genotype-1 HCV infection due to high rates of relapse. Nonetheless, the biologic correlates identified in this study likely have relevance for understanding why relapse still occurs in a subset of subjects receiving current regimens, and as such these findings will benefit from further validation using samples from cohorts receiving ribavirin-free regimens.


In conclusion, neutrophil count pre-treatment and NK-cell count post-treatment distinguish patients achieving SVR from those who relapse after sofosbuvir and ribavirin treatment. In addition, expression of interferon related genes and genes related to T-cell dysfunction differed by outcome, supporting a role for host immunity in modulating HCV treatment outcome with DAA therapy. These findings suggest that favorable host immunity could enable higher response rates and shorter durations of therapy, which could have significant economic and adherence implications.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Direct acting antiviral


Hepatitis C virus


National Institute of Allergy and Infectious Diseases


Natural Killer cell


Peripheral blood mononuclear cells


Quantitative reverse transcriptase-polymerase chain reaction


Resistance associated variant


Sustained Virologic Response


  1. Lawitz E, Poordad F, Gutierrez JA, Wells JT, Landaverde CE, Evans B, et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: a randomized trial. Hepatology. 2017;65(2):439–.

  2. Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology. 2016;151(5):893–901 e1.

    Article  CAS  Google Scholar 

  3. Kattakuzhy S, Wilson E, Sidharthan S, Sims Z, McLaughlin M, Price A, et al. Moderate sustained Virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis. 2016;62(4):440–7.

    CAS  PubMed  Google Scholar 

  4. Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, Nonrandomized Trial. Ann Intern Med. 2015;163(12):899–907.

    Article  Google Scholar 

  5. Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol. 2016;1(2):97–104.

    Article  Google Scholar 

  6. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486–504.

    Article  Google Scholar 

  7. Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O'Rear JJ, et al. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of Elbasvir and Grazoprevir. Gastroenterology. 2017;152(3):586–97.

    Article  CAS  Google Scholar 

  8. Kish T, Aziz A, Sorio M. Hepatitis C in a new era: a review of current therapies. P T. 2017;42(5):316–29.

    PubMed  PubMed Central  Google Scholar 

  9. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.

    Article  CAS  Google Scholar 

  10. Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, Janssen HL, et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis. 2016;213(2):216–23.

    Article  CAS  Google Scholar 

  11. Shrivastava S, Wilson E, Poonia B, Tang L, Osinusi A, Kohli A, et al. Augmentation of HCV specific immunity and sustained virological response (SVR). J Viral Hepat. 2017;24(9):742-9.

  12. Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, McLean A, Hudson E, et al. Impact of IFNL4 genotype on interferon-stimulated gene expression during DAA therapy for hepatitis C. Hepatology. 2018;68(3):859-71.

  13. Carlton-Smith C, Holmes JA, Naggie S, Lidofsky A, Lauer GM, Kim AY, et al. IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. J Viral Hepat. 2018;25(5):465–72.

    Article  CAS  Google Scholar 

  14. Meissner EG, Wu D, Osinusi A, Bon D, Virtaneva K, Sturdevant D, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest. 2014;124(8):3352–63.

    Article  CAS  Google Scholar 

  15. Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, et al. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016;23(7):496–505.

    Article  CAS  Google Scholar 

  16. Meissner EG, Kohli A, Higgins J, Lee YJ, Prokunina O, Wu D, et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun. 2017;1(7):586–94.

    Article  CAS  Google Scholar 

  17. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804–11.

    Article  CAS  Google Scholar 

  18. Swaminathan S, Hu Z, Rupert AW, Higgins JM, Dewar RL, Stevens R, et al. Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection. PLoS One. 2014;9(6):e98989.

    Article  Google Scholar 

  19. Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer. 2017;5:18.

    Article  Google Scholar 

  20. Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Ribavirin reduces absolute lymphocyte counts in hepatitis C virus-infected patients treated with interferon-free, Direct-Acting Antiviral Regimens. Clin Infect Dis. 2015;61(6):974–7.

    Article  CAS  Google Scholar 

  21. Robinson MW, Swann R, Sigruener A, Barclay ST, Mills PR, McLauchlan J, et al. Elevated interferon-stimulated gene transcription in peripheral blood mononuclear cells occurs in patients infected with genotype 1 but not genotype 3 hepatitis C virus. J Viral Hepat. 2014;22(4):384-90.

  22. Rosenberg BR, Freije CA, Imanaka N, Chen ST, Eitson JL, Caron R, et al. Genetic variation at IFNL4 influences Extrahepatic interferon-stimulated gene expression in chronic HCV patients. J Infect Dis. 2018;217(4):650–5.

    Article  CAS  Google Scholar 

  23. Lalle E, Bordi L, Caglioti C, Garbuglia AR, Castilletti C, Taibi C, et al. IFN-Alpha receptor-1 upregulation in PBMC from HCV naive patients carrying cc genotype. possible role of IFN-lambda. PLoS One. 2014;9(4):e93434.

    Article  Google Scholar 

  24. Menezes EG, Coelho-Dos-Reis JG, Cardoso LM, Lopes-Ribeiro A, Jonathan-Goncalves J, Porto Goncalves MT, et al. Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases. Antivir Res. 2017;141:19–28.

    Article  CAS  Google Scholar 

  25. Egli A, Santer DM, O'Shea D, Tyrrell DL, Houghton M. The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections. Emerg Microbes Infect. 2014;3(7):e51.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978–88.

    Article  CAS  Google Scholar 

  27. Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, et al. IFN-lambda4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199(11):3808-20.

  28. Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36(5):1273–9.

    Article  CAS  Google Scholar 

  29. Giorgini A, Capsoni F, Podda M, Lleo A, Battezzati PM, Ongari AM, et al. Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. Ann N Y Acad Sci. 2009;1173:847–57.

    Article  CAS  Google Scholar 

  30. Golden-Mason L, McMahan RH, Kriss MS, Kilgore AL, Cheng L, Dran RJ, et al. Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment. Hepatol Commun. 2018;2(4):364–75.

    Article  CAS  Google Scholar 

  31. Kramer B, Finnemann C, Sastre B, Lutz P, Glassner A, Wolter F, et al. IL-28B genetic variants determine the extent of monocyte-induced activation of NK cells in hepatitis C. PLoS One. 2016;11(9):e0162068.

    Article  Google Scholar 

  32. Rogalska-Taranta M, Markova AA, Taranta A, Lunemann S, Schlaphoff V, Flisiak R, et al. Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. J Leukoc Biol. 2015;98(2):283–94.

    Article  CAS  Google Scholar 

  33. Boisvert M, Shoukry NH. Type III Interferons in hepatitis C virus infection. Front Immunol. 2016;7:628.

    Article  Google Scholar 

  34. Paolini R, Bernardini G, Molfetta R, Santoni A. NK cells and interferons. Cytokine Growth Factor Rev. 2015;26(2):113–20.

    Article  CAS  Google Scholar 

  35. Fuertes Marraco SA, Neubert NJ, Verdeil G, Speiser DE. Inhibitory receptors beyond T cell exhaustion. Front Immunol. 2015;6:310.

    Article  Google Scholar 

  36. Owusu Sekyere S, Suneetha PV, Kraft AR, Zhang S, Dietz J, Sarrazin C, et al. A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J Hepatol. 2015;62(1):31–40.

    Article  CAS  Google Scholar 

  37. Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540–54 e12.

    Article  CAS  Google Scholar 

  38. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–78.

    Article  CAS  Google Scholar 

  39. Mondelli MU. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? Hepatology. 2014;60(4):1126–9.

    Article  CAS  Google Scholar 

Download references


Acknowledgments: The authors would like to thank the investigators and participants of the clinical trial from which the samples analyzed in this study were derived.


This study was funded by the National Institute of Allergy and Infectious Diseases grant K08AI121348 (EGM). This project was also funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E, the National Institute of Allergy and Infectious Diseases, and the NIH Critical Care Medicine Department. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Author information

Authors and Affiliations



CO and EGM conducted the experiments. HM, SK, and EGM designed the study. WX performed the statistical analysis. All authors contributed to the drafting and editing of the manuscript.

Author’s information

Not applicable

Corresponding author

Correspondence to Eric G. Meissner.

Ethics declarations

Ethics approval and consent to participate

This study received approval from the Institutional Review Boards at NIAID and the Medical University of South Carolina and was conducted in concordance with the 1975 Declaration of Helsinki. All patients provided written informed consent, as previously reported with initial publication of the clinical trial result [17], which included permissions to use samples and data collected in the trial for future studies.

Consent for publication

Not applicable.

Competing interests

Wenjie Xu is an employee of Nanostring Technologies. Authors CO, SK, HM, and EGM declare they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Supplemental Fig. 1

: Overview of raw gene expression data. Hierarchical clustering of samples based on similarity of global gene expression. Shown are potentially clinically relevant variables including treatment response (SVR vs REL), gender (male, female), ribavirin dose (weight-based versus low dose ribavirin), fibrosis score (HAI fibrosis), IFNL4 genotype (rs368234815 locus where 2 = ΔG allele and 1 = T allele), and ALT level. Whether samples were pre or post-treatment is shown on the bottom x-axis.

Additional file 2: Supplemental Fig. 2

: Predictive capacity of genes expressed pre-treatment. Shown is a heatmap of genes identified by machine learning algorithm to best associate with outcome, performance of the training gene set by predictive score and AUC, and performance of the gene set when the data were re-analyzed with by cross-validation runs.

Additional file 3: Supplemental Fig. 3

: Predictive capacity of genes expressed post-treatment. Shown is a heatmap of genes identified by machine learning algorithm to best associate with outcome, performance of the training gene set by predictive score and AUC, and performance of the gene set when the data were re-analyzed with by cross-validation runs.

Additional file 4: Supplemental Table 1

: Genes on Nanostring Immunology panel used to assess cell-type frequency in whole blood.

Additional file 5.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orr, C., Xu, W., Masur, H. et al. Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection. BMC Infect Dis 20, 929 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: